SCHEMBL30862713

SCHEMBL30862713

O=C(Nc1ccc(C(F)(F)F)cc1)[C@H]1CCc2c(N3CCNCC3)c(=O)n3nc(C4=CCOCC4)nc3n21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.41
▸ PIK3CA P42336 4/20 0.34
▸ MTOR P42345 4/20 0.34
▸ FLT3 P36888 1/20 0.33
▸ MAPKAPK2 P49137 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ TRPV1 Q8NER1 2/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ JAK1 P23458 1/20 0.32
▸ MAPT P10636 2/20 0.32
▸ USP2 O75604 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ BRAF P15056 2/20 0.31
▸ RHOC P08134 1/20 0.31
▸ RHOA P61586 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30862847 1.00 WRN (0.41) WRNPIK3CAMTORFLT3MAPKAPK2
SCHEMBL30862683 1.00 WRN (0.41) WRNPIK3CAMTORFLT3MAPKAPK2
SCHEMBL30862836 0.90 WRN (0.46) WRNPIK3CAMTORMEN1POLB
SCHEMBL27386392 0.90 WRN (0.46) WRNPIK3CAMTORMEN1POLB
SCHEMBL30862843 0.90 WRN (0.47) WRNFLT3BRAF
SCHEMBL30862695 0.90 WRN (0.47) WRNFLT3BRAF
SCHEMBL30862758 0.88 WRN (0.44) WRNPIK3CAMTORMEN1KMT2A
SCHEMBL30862692 0.88 WRN (0.44) WRNPIK3CAMTORMEN1KMT2A
SCHEMBL30862728 0.86 TRPV1 (0.40) PIK3CAMTORMAPKAPK2TRPV1JAK2
SCHEMBL27386868 0.85 WRN (0.48) WRNPIK3CAMTORTRPV1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601746-A1 TRICYCLIC COMPOUNDS AND THEIR USES Novartis AG (CH) 2025-08-20 — — EP disclosed
CN-120077048-A Tricyclic compounds and uses thereof 诺华股份有限公司 2025-05-30 — — CN disclosed
US-20240245694-A1 Tricyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-07-25 — — US disclosed
WO-2024079623-A1 TRICYCLIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240245694-A1 Tricyclic Compounds and their Uses F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R WRN 2992/4885PIK3CA 1817/4885MTOR 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback